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ABSTRACT
Objective The prognostic importance of changes in
ischaemic ECG abnormalities over time (especially ST-T
abnormalities) among Asians has not been fully
investigated. We examined the associations between
changes in ischaemic abnormalities upon serial ECG
(improvement, persistence, deterioration) and
cardiovascular disease (CVD) risk.
Methods A prospective study cohort was conducted
with 9374 men and women aged 40–69 years in four
communities. Participants had multiple ECGs at study
entry and during the next 10 years, and were followed
up for a median period of 23.0 years. Total CVD (stroke
and coronary heart disease) was ascertained under
systematic surveillance. ECG abnormalities were deﬁned
by the Minnesota Code, ST depression (Code4),
abnormal T wave (Code5) and categorised into nine
groups (no–no, no–minor, no–major, minor–no, minor–
minor, minor–major, major–no, major–minor, major–
major) by comparison with the point of entrance and
maximum change.
Results We documented 1196 CVD events. Compared
with no–no abnormality, no–minor, minor–major and
major–major in Code4, HRs (95% CI) adjusted for
cardiovascular risk factors were 1.19 (1.00–1.42), 1.57
(1.15–2.12) and 1.87 (1.42–2.47). Similar results were
observed in Code5.
Conclusions Changes in ischaemic ECG abnormalities
from none to minor, and minor to major, as well as
persistent major abnormalities, were associated with an
increased risk of CVD.
INTRODUCTION
The most common ﬁndings of ischaemic ECG are
ST-segment or T-wave abnormalities, or both (‘ST-T
abnormalities’).1 Prospective studies have shown that
these abnormalities are associated with an increased
risk of cardiovascular disease (CVD).1–6 We investi-
gated the relationship between non-speciﬁc minor or
major ST-T abnormalities and the prevalence of
stroke among Japanese men.2 Those studies exam-
ined a single ECG abnormality as a predictor of
CVD.
However, we believe that changes in ECG abnor-
malities over time should be explored because a
single ECG measurement may not be sufﬁcient to
estimate long-term ischaemic abnormalities.
Therefore, we focused on changes in ST-T abnor-
malities (ie, persistent or worsening changes in
ischaemic ECG abnormalities). Previous cohort
studies from the Europe and the USA that have
collected repeat ECGs showed that persistent and
new ECG abnormalities were associated with an
increased risk of CVD.3 4
We hypothesise that worsening changes in ST-T
abnormalities may be associated strongly with CVD
risk. Thus, we aimed to ascertain if changes in
ECG abnormalities in annual examinations for
11 years were associated with a subsequent risk of
CVD in a general population in Japan within the
Circulatory Risk in Communities Study (CIRCS).
METHODS
Study population
The CIRCS is a population-based cohort study of
cardiovascular risk factors and CVD incidence in
Japanese populations. Details of the design and
methods of the study are described elsewhere.2 7
Brieﬂy, subjects were Japanese residents living in
rural or suburban communities from 1975 to
1987: the town of Ikawa, Noichi and Kyowa; the
city of Yao. Participants underwent an extensive
examination (including 12-lead ECG at rest) at
study entry that was repeated annually for the next
decade. The present study used data from the ﬁrst
11 ECG examinations (ie, at study entry and ﬁrst
10 annual re-examinations) (ﬁgure 1). The target
population of the present study was 11 611 men and
women aged 40–69 years at study entry (ﬁgure 2).
We excluded persons with missing data for ECG,
body mass index (BMI) and blood pressure (BP)
and subjects with a history of CVD at study entry
(n=517). We also excluded 38 participants with
baseline ECG abnormalities that included abnormal
Q and QS patterns because these codes were
regarded as having ‘old’ myocardial infarction.1
During the 10 subsequent annual examinations,
1621 persons had no second ECG and 61 persons
had CVD events or moved from the area before the
10th annual examination, so we excluded them
from analyses. The remaining 9374 participants
constituted the study cohort.
ECG measurements at study entry
Standard 12-lead ECG at rest was recorded in the
supine position. Each record was coded independ-
ently according to the Minnesota Code by two
trained physicians.8 Agreement for classiﬁcation of
the Minnesota Code was accepted, and disagree-
ments were discussed between the two physicians
until a consensus was reached.
We handled ST-segment abnormalities (Code4)
and T-wave abnormalities (Code5) of the
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Figure 1 Changes in ECG
abnormalities.
Figure 2 Flow chart showing the
number of participants at each phase.
BMI, body mass index; CVD,
cardiovascular disease.
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Minnesota Code, which are indices of ischaemia.1 The agree-
ment for ECG abnormalities in Code4 and Code5 was estimated
by calculation of the kappa coefﬁcient. The 4-1 and 4-2 of
Code4 were deﬁned as a ‘major abnormality’; 4-3, 4-4 and
modiﬁed 4-5 of Code4 were deﬁned as a ‘minor abnormality’;
5-1 and 5-2 of Code5 were deﬁned as a major abnormality; 5-3,
5-4 and modiﬁed 5-5 of Code5 were deﬁned as a minor abnor-
mality.2 8 Subjects with both major and minor abnormalities
were classiﬁed as having a major.
ECG measurements during annual examinations
Serial ECGs at study entry and during annual examinations of
the same person were used to examine changes in ECG abnor-
malities, categorised according to comparison with that at study
entry and the point of maximum change during the subsequent
10 annual examinations. With respect to Code4 and Code5,
participants were classiﬁed into nine groups: changing from no
abnormalities at study entry to no abnormalities later (no–no
abnormality); from no to minor (no–minor abnormality); from
no to major (no–major abnormality); from minor to none
(minor–no abnormality); from minor to minor (minor–minor
abnormality); from minor to major (minor–major abnormality);
from major to none (major–no abnormality); from major to
minor (major–minor abnormality) and from major to major
(major–major abnormality).
The individual follow-up time was censored if a major
abnormality occurred ﬁrst (ﬁgure 1). If there was no major
abnormality during the 10 annual examinations, the follow-up
time was censored if a minor abnormality occurred ﬁrst. If
there was no minor abnormality before the 10th annual
re-examination, the follow-up time was censored if the ﬁnal
ECG was done.
Endpoint determination
The details of endpoint determination have been described else-
where.2 7 For all residents, CVD events were ascertained by ﬁve
overlapping methods: reports by public-health nurses and health
volunteers; annual surveys of cardiovascular risk; national insur-
ance claims; reports by local physicians and death certiﬁcates.
To conﬁrm the diagnosis, all living patients were telephoned
and/or visited to obtain their medical histories in addition to
reviews of their medical records in hospitals and local clinics. In
cases of deaths with underlying causes of stroke or coronary
heart disease (CHD), we obtained medical histories and/or
reviewed medical records. The primary focus of our study was
on associations of changing status of ST-T abnormalities with the
risk of CVD events, but the results for stroke and CHD are pre-
sented separately.
Criteria for incident stroke were deﬁned as a focal neuro-
logical deﬁcit of rapid onset and lasting ≥24 hours or until
death.2 7 The determination of stroke subtypes was done pri-
marily by using ﬁndings of CT/MRI, which were available for
81.6% of stroke cases. Stroke subtypes were deﬁned as ‘intracer-
ebral haemorrhage’, ‘subarachnoid haemorrhage’, ‘ischaemic
stroke’ and ‘unclassiﬁed stroke’. Strokes were diagnosed clinic-
ally but that did not show a lesion on imaging were classiﬁed
according to clinical criteria. Criteria for incident CHD (ie, def-
inite sudden cardiac death <1 hour of onset, deﬁnite angina
pectoris, deﬁnite and probable myocardial infarction) have been
described.7 The ﬁnal diagnosis for the CVD endpoint was made
by physicians and epidemiologists blinded to survey data of car-
diovascular risk factors.
Follow-up lasted until the end of 2010 for Ikawa, Kyowa and
Yao, and until the end of 2007 for Noichi. During subsequent
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follow-up, 593 persons moved out of the community and 3694
died, and they were censored at the date of moving out of the
community or the date of death, respectively.
Statistical analysis
Values are the mean±SD or percentages, as appropriate.
Analyses of covariance were used to test differences in
age-adjusted and gender-adjusted means and proportions of
characteristics at study entry according to the categories of ECG
abnormalities set out in Code4 and Code5. HRs and 95% CIs
of CVD prevalence were calculated with reference to the HR of
persons without ECG abnormalities using a Cox proportional
hazards regression model adjusted for risk factors for CVD.
Covariates were these factors: age and gender for model 1;
model 1 plus systolic BP, antihypertensive medication, BMI,
smoking category (never, past or daily), category of alcohol
intake (never, past, current <46 or current ≥46 g/day), serum
levels of total cholesterol9 and diabetic type for model 2; model
2 plus other ECG abnormalities at study entry, high R-wave
(Minnesota Code 3-1),8 10 ventricular premature beats
(Minnesota Code 8-1-2)8 11 and atrial ﬁbrillation (Minnesota
Code 8-3-1)8 12 that were associated with CVD risk in our
study for model 3; model 3 plus identical ECG abnormalities
during subsequent annual 10 years examinations for model
4. ‘Diabetic type’ was deﬁned as a fasting glucose level of
≥126 mg/dL and/or a non-fasting glucose level of ≥200 mg/dL,
and/or current use of medication for the treatment of diabetes
mellitus. Person-years were calculated as the sum of individual
follow-up time until CVD, emigration, death or the end of
follow-up. If participants suffered a stroke, sudden cardiac
death, angina pectoris or myocardial infarction, the shortest
person-years was adopted. Subjects who had moved away from
the community or died were treated as censored cases. Statistical
analyses were done with SAS V.9.4. and p<0.05 (two-tailed)
was considered signiﬁcant.
RESULTS
ECG abnormalities at study entry
Characteristics of participants are shown in table 1. Of the 11
056 persons (4417 men and 6639 women) at study entry, mean
(SD) of age was 52.9 (8.7) years. Mean values of age, BMI, sys-
tolic BP, diastolic BP, alcohol intake, serum levels of total choles-
terol, proportion of use of antihypertensive medication and
diabetic type were progressively and gradually higher according
to ECG worsening, from none, minor to major abnormalities.
During a follow-up of 25.5 years, 1468 CVDs were documen-
ted. Persons with ECG abnormalities at study entry had a higher
age-adjusted and gender-adjusted HR of total CVD than did
those without ECG abnormalities (table 2). The multivariable
HR (95% CI) of total CVD adjusted for cardiovascular risk
factors (model 2) was 1.21 (1.03–1.42) for a Code4 minor
abnormality and 1.69 (1.36–2.10) for a Code4 major abnormal-
ity. Regarding Code5, the corresponding multivariable HR of
total CVD (model 2) was 1.25 (1.06–1.46) and 2.16 (1.72–
2.70). After further adjustment for other ECG abnormalities at
study entry (model 3), the results did not change materially. A
moderate association was found between Code4 and Code5
abnormalities at study entry. The proportion of cases having
both Code4 and Code5 abnormalities was 6.0% (n=667) and
the kappa coefﬁcient for the agreement of these abnormalities
was 0.41. The multivariable HR (95% CI) of total CVD for
having both Code4 and Code5 abnormalities (model 2) was
1.71 (1.44–2.03), whereas the corresponding HR of having
only a Code4 abnormality was 1.00 (0.82–1.23) and the corre-
sponding HR of having only a Code5 abnormality was 1.13
(0.92–1.39) (data not shown).
Women with minor abnormalities in Code4 and Code5 were
not associated with subsequent CVD risk (see online
supplementary table S1). In women, the multivariable HR (95%
CI) of total CVD (model 2) was 0.94 (0.76–1.17) for a Code4
minor abnormality and 1.09 (0.88–1.34) for a Code5 minor
abnormality. Results of total CVD were similar between men
and women for the other men or women groups.
Changes in ECG abnormalities
During a follow-up of 23.0 years, out of 9374 participants
(3545 men and 5829 women), 1196 CVDs were documented.
The median observation time for patterns of changes of ECG
abnormalities before commencing follow-up was 2.0–5.2 years
(see online supplementary table S2).
Table 2 HRs and 95% CIs of cardiovascular disease (CVD) for ECG abnormalities in Code4 and 5 at study entry
Minnesota Code At entry No. at risk Stroke Coronary heart disease Total CVD
Code4 No 9620 Cases 908 (reference) 307 (reference) 1191 (reference)
Minor 1086 Cases 140 45 181
Age-adjusted and gender-adjusted HR (model 1) 1.44 (1.20–1.72)*** 1.47 (1.07–2.02)* 1.45 (1.24–1.70)***
Multivariate-adjusted HR (model 2) 1.19 (0.99–1.43) 1.23 (0.89–1.71) 1.21 (1.03–1.42)*
Multivariate-adjusted HR (model 3) 1.16 (0.96–1.39) 1.21 (0.87–1.67) 1.18 (1.01–1.39)*
Major 350 Cases 77 22 96
Age-adjusted and gender-adjusted HR (model 1) 2.49 (1.97–3.15)*** 2.30 (1.49–3.56)*** 2.46 (1.99–3.03)***
Multivariate-adjusted HR (model 2) 1.70 (1.33–2.16)*** 1.61 (1.03–2.54)* 1.69 (1.36–2.10)***
Multivariate-adjusted HR (model 3) 1.57 (1.22–2.02)*** 1.47 (0.93–2.34) 1.57 (1.26–1.96)***
Code5 No 9733 Cases 924 (reference) 297 (reference) 1194 (reference)
Minor 1014 Cases 137 52 188
Age-adjusted and gender-adjusted HR (model 1) 1.43 (1.19–1.71)*** 1.81 (1.34–2.44)*** 1.56 (1.33–1.82)***
Multivariate-adjusted HR (model 2) 1.12 (0.93–1.35) 1.50 (1.10–2.04)** 1.25 (1.06–1.46)**
Multivariate-adjusted HR (model 3) 1.08 (0.90–1.30) 1.48 (1.09–2.02)* 1.21 (1.03–1.42)*
Major 309 Cases 64 25 86
Age-adjusted and gender-adjusted HR (model 1) 2.54 (1.97–3.28)*** 3.53 (2.33–5.33)*** 2.76 (2.21–3.45)***
Multivariate-adjusted HR (model 2) 1.96 (1.51–2.54)*** 2.76 (1.81–4.22)*** 2.16 (1.72–2.70)***
　 　 Multivariate-adjusted HR (model 3) 1.90 (1.46–2.47)*** 2.65 (1.73–4.06)*** 2.10 (1.67–2.63)***
Model 2: covariates were age, gender, systolic blood pressure, antihypertensive medication, body mass index, smoking category (never, past or current smokers), alcohol intake category
(never, past, current <46, current ≥46 g/day), serum total cholesterol and diabetic type.
Model 3: covariates comprised model 2 plus other ECG abnormalities (high R-wave, ventricular premature beats, atrial fibrillation) at study entry.
*p<0.05, **p<0.01, ***p<0.001.
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Table 3 shows the HR (95% CI) of CVD for each pattern of
changes in abnormalities in Code4 compared with the pattern
of no–no ECG abnormality as shown in models 1–4. Regarding
Code4, patterns of no–minor, minor–major and major–major
abnormalities had the higher multivariable HR of CVD. The
corresponding multivariable HR (95% CI) of total CVD
for Code4 was 1.19 (1.00–1.42), 1.57 (1.15–2.12) and 1.87
(1.42–2.47) in model 2. Other patterns except for no–minor,
minor–major and major–major abnormalities had no signiﬁcant
association between changes in ECG abnormality and risk
of total CVD. In men, the corresponding multivariable HR
(95% CI) was 1.48 (1.11–1.97), 2.35 (1.48–3.74) and 3.02
(2.00–4.56), and in women, the corresponding multivariable
HR (95% CI) was 1.08 (0.86–1.34), 1.21 (0.81–1.81) and 1.34
(0.91–1.96) (data not shown). With regard to the impact of
other ECG abnormalities, the multivariable HR (95% CI) of
total CVD was 1.27 (1.12–1.44) for high R-wave, 1.90 (1.27–
2.86) for ventricular premature beats and 2.80 (1.88–4.16) for
atrial ﬁbrillation. For further adjustment in models 3 and 4, the
multivariable HR of total CVD was attenuated, but results for
statistical signiﬁcance did not change materially. Table 4 shows
the HR (95% CI) of CVD for each pattern of changes in abnor-
malities in Code5. The multivariable HR of CVD in patterns of
no–minor, minor–major and major–major abnormalities in
Table 3 HRs and 95% CIs of cardiovascular disease (CVD) according to changes in ECG abnormalities in Code4
Minnesota
Code At entry
After 10 years
annual
examination
No. at
risk Stroke
Coronary heart
disease Total CVD
Code4 No → None 6759 Cases 586 (reference) 197 (reference) 769 (reference)
No → Minor 1182 Cases 133 38 165
Age-adjusted and gender-adjusted HR
(model 1)
1.38 (1.14 –1.67)** 1.30 (0.91–1.85) 1.33 (1.12–1.58)**
Multivariate-adjusted HR (model 2) 1.23 (1.02–1.50)* 1.17 (0.82–1.68) 1.19 (1.00–1.42)*
Multivariate-adjusted HR (model 3) 1.22 (1.00–1.48)* 1.14 (0.80–1.64) 1.17 (0.99–1.40)
Multivariate-adjusted HR (model 4) 1.20 (0.99–1.47) 1.11 (0.77–1.60) 1.16 (0.97–1.38)
No → Major 237 Cases 32 10 41
Age-adjusted and gender-adjusted HR
(model 1)
1.54 (1.08–2.20)* 1.48 (0.78–2.80) 1.50 (1.10–2.06)*
Multivariate-adjusted HR (model 2) 1.19 (0.82–1.71) 1.17 (0.61–2.24) 1.17 (0.85–1.62)
Multivariate-adjusted HR (model 3) 1.14 (0.79–1.65) 1.09 (0.57–2.09) 1.12 (0.81–1.55)
Multivariate-adjusted HR (model 4) 1.08 (0.75–1.56) 1.05 (0.54–2.02) 1.06 (0.77–1.47)
Minor → No 283 Cases 25 9 33
Age-adjusted and gender-adjusted HR
(model 1)
1.22 (0.81–1.82) 1.39 (0.71–2.72) 1.25 (0.88–1.78)
Multivariate-adjusted HR (model 2) 1.08 (0.72–1.61) 1.18 (0.60–2.33) 1.11 (0.78–1.58)
Multivariate-adjusted HR (model 3) 1.08 (0.72–1.63) 1.18 (0.60–2.33) 1.12 (0.79–1.60)
Multivariate-adjusted HR (model 4) 1.07 (0.71–1.61) 1.22 (0.61–2.41) 1.12 (0.78–1.59)
Minor → Minor 397 Cases 50 15 64
Age-adjusted and gender-adjusted HR
(model 1)
1.40 (1.05–1.88)* 1.37 (0.81–2.34) 1.41 (1.09–1.83)**
Multivariate-adjusted HR (model 2) 1.12 (0.83–1.51) 1.18 (0.69–2.02) 1.15 (0.88–1.49)
Multivariate-adjusted HR (model 3) 1.10 (0.81–1.48) 1.17 (0.68–2.01) 1.13 (0.87–1.47)
Multivariate-adjusted HR (model 4) 1.07 (0.79–1.44) 1.14 (0.66–1.96) 1.10 (0.84–1.43)
Minor → Major 226 Cases 35 12 47
Age-adjusted and gender-adjusted HR
(model 1)
2.00 (1.41–2.81)*** 2.13 (1.18–3.84)* 2.08 (1.54–2.80)***
Multivariate-adjusted HR (model 2) 1.46 (1.03–2.08)* 1.72 (0.94–3.16) 1.57 (1.15–2.12)**
Multivariate-adjusted HR (model 3) 1.44 (1.01–2.06)* 1.56 (0.84–2.90) 1.52 (1.11–2.07)**
Multivariate-adjusted HR (model 4) 1.41 (0.98–2.02) 1.50 (0.81–2.80) 1.47 (1.08–2.01)*
Major → No 24 Cases 2 2 4
Age-adjusted and gender-adjusted HR
(model 1)
1.16 (0.29–4.63) 3.77 (0.94–15.22) 1.86 (0.70–4.96)
Multivariate-adjusted HR (model 2) 0.93 (0.23–3.76) 2.58 (0.63–10.53) 1.48 (0.55–3.96)
Multivariate-adjusted HR (model 3) 0.95 (0.24–3.82) 2.61 (0.64–10.67) 1.50 (0.56–4.03)
Multivariate-adjusted HR (model 4) 0.97 (0.24–3.92) 2.56 (0.62–10.49) 1.52 (0.57–4.07)
Major → Minor 56 Cases 10 1 11
Age-adjusted and gender-adjusted HR
(model 1)
1.95 (1.04–3.64)* 0.64 (0.09–4.58) 1.67 (0.92–3.03)
Multivariate-adjusted HR (model 2) 1.56 (0.83–2.93) 0.46 (0.06–3.31) 1.33 (0.73–2.42)
Multivariate-adjusted HR (model 3) 1.52 (0.81–2.88) 0.41 (0.06–2.95) 1.28 (0.70–2.35)
Multivariate-adjusted HR (model 4) 1.47 (0.78–2.78) 0.39 (0.05–2.80) 1.24 (0.68–2.27)
Major → Major 210 Cases 49 16 62
Age-adjusted and gender-adjusted HR
(model 1)
2.77 (2.06–3.72)*** 2.86 (1.70–4.80)*** 2.75 (2.11–3.57)***
Multivariate-adjusted HR (model 2) 1.80 (1.32–2.47)*** 2.18 (1.26–3.77)** 1.87 (1.42–2.47)***
Multivariate-adjusted HR (model 3) 1.66 (1.19–2.30)** 1.90 (1.08–3.36)* 1.70 (1.28–2.28)***
Multivariate-adjusted HR (model 4) 1.51 (1.08–2.10)* 1.81 (1.02–3.21)* 1.58 (1.18–2.12)**
Model 2: covariates were age, gender, systolic blood pressure, antihypertensive medication, body mass index, smoking category (never, past or current smokers), alcohol intake category
(never, past, current <46, current ≥46 g/day), serum total cholesterol and diabetic type.
Model 3: covariates comprised model 2 plus other ECG abnormalities (high R-wave, ventricular premature beats, atrial fibrillation) at study entry.
Model 4: covariates comprised model 3 plus changes in other ECG abnormalities (high R-wave, ventricular premature beats, atrial fibrillation) during follow-up.
*p<0.05, **p<0.01, ***p<0.001.
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Code5 was 1.42 (1.19–1.69), 1.95 (1.46–2.61) and 2.56 (1.95–
3.36) in model 2. In men, the corresponding multivariable HR
(95% CI) was 1.62 (1.23–2.12), 2.39 (1.53–3.74) and 3.26
(2.10–5.04), and in women, the corresponding multivariable
HR (95% CI) was 1.32 (1.06–1.66), 1.69 (1.15–2.48) and 2.19
(1.53–3.12) (data not shown). For further adjustment in models
3 and 4, the multivariable HR of total CVD did not change
materially.
The multivariable HR of stroke showed similar results to
those of total CVD. The multivariable HR of CHD was signiﬁ-
cant only for a major–major ECG abnormality compared with a
no–no abnormality.
DISCUSSION
Worsening changes in ischaemic ECG abnormalities were asso-
ciated with an increased risk of total CVD by 19% for a new
minor abnormality in Code4; 57% for changing to a major
abnormality from a minor abnormality in Code4; 42% for a
new minor abnormality in Code5 and 95% for changing to a
major abnormality from a minor abnormality in Code5.
Persistent major abnormalities at a particularly high risk of CVD
events were found to increase by 87% in Code4 and by 156%
in Code5.
A cohort study of 1221 Swedish men with a follow-up of
32 years collected repeat ECGs at 50 and 70 years of age and
Table 4 HRs and 95% CIs of cardiovascular disease (CVD) according to changes in ECG abnormalities in Code5
Minnesota
Code At entry
After 10 years
annual
examination
No. at
risk Stroke
Coronary heart
disease Total CVD
Code5 No → None 6900 Cases 598 (reference) 192 (reference) 774 (reference)
No → Minor 1101 Cases 138 37 170
Age-adjusted and gender-adjusted HR
(model 1)
1.69 (1.40–2.03)*** 1.51 (1.06–2.16)* 1.63 (1.38–1.93)***
Multivariate-adjusted HR (model 2) 1.44 (1.19–1.74)*** 1.38 (0.96–1.99) 1.42 (1.19–1.69)***
Multivariate-adjusted HR (model 3) 1.43 (1.17–1.73)*** 1.37 (0.95–1.98) 1.41 (1.18–1.67)***
Multivariate-adjusted HR (model 4) 1.40 (1.15–1.70)*** 1.35 (0.93–1.95) 1.38 (1.16–1.64)***
No → Major 239 Cases 23 11 32
Age-adjusted and gender-adjusted HR
(model 1)
1.41 (0.93–2.14) 2.27 (1.23–4.19)** 1.54 (1.08–2.19)*
Multivariate-adjusted HR (model 2) 1.15 (0.76–1.76) 2.07 (1.12–3.84)* 1.29 (0.90–1.85)
Multivariate-adjusted HR (model 3) 1.09 (0.71–1.67) 1.95 (1.05–3.64)* 1.23 (0.86–1.76)
Multivariate-adjusted HR (model 4) 1.03 (0.67–1.57) 1.92 (1.03–3.59)* 1.17 (0.82–1.68)
Minor → No 178 Cases 11 11 22
Age-adjusted and gender-adjusted HR
(model 1)
0.74 (0.41–1.34) 2.54 (1.38–4.68)** 1.18 (0.77–1.80)
Multivariate-adjusted HR (model 2) 0.63 (0.34–1.14) 2.19 (1.18–4.05)* 1.01 (0.66–1.55)
Multivariate-adjusted HR (model 3) 0.58 (0.32–1.06) 2.10 (1.13–3.91)* 0.95 (0.62–1.46)
Multivariate-adjusted HR (model 4) 0.58 (0.32–1.06) 2.10 (1.13–3.90)* 0.95 (0.62–1.45)
Minor → Minor 488 Cases 61 19 79
Age-adjusted and gender-adjusted HR
(model 1)
1.48 (1.13–1.93)** 1.55 (0.96–2.49) 1.52 (1.20–1.92)***
Multivariate-adjusted HR (model 2) 1.19 (0.90–1.56) 1.36 (0.83–2.21) 1.24 (0.98–1.58)
Multivariate-adjusted HR (model 3) 1.17 (0.89–1.54) 1.36 (0.83–2.22) 1.23 (0.97–1.57)
Multivariate-adjusted HR (model 4) 1.15 (0.88–1.52) 1.33 (0.81–2.18) 1.21 (0.95–1.54)
Minor → Major 212 Cases 43 10 53
Age-adjusted and gender-adjusted HR
(model 1)
2.65 (1.94–3.62)*** 1.97 (1.04–3.74)* 2.56 (1.93–3.39)***
Multivariate-adjusted HR (model 2) 1.96 (1.42–2.70)*** 1.72 (0.89–3.31) 1.95 (1.46–2.61)***
Multivariate-adjusted HR (model 3) 1.86 (1.34–2.58)*** 1.69 (0.87–3.27) 1.88 (1.40–2.52)***
Multivariate-adjusted HR (model 4) 1.83 (1.32–2.55)*** 1.66 (0.86–3.22) 1.85 (1.38–2.48)***
Major → No 30 Cases 3 1 4
Age-adjusted and gender-adjusted HR
(model 1)
1.63 (0.52–5.06) 1.96 (0.27–14.00) 1.71 (0.64–4.56)
Multivariate-adjusted HR (model 2) 1.61 (0.52–5.04) 1.71 (0.24–12.35) 1.65 (0.61–4.42)
Multivariate-adjusted HR (model 3) 1.63 (0.52–5.11) 1.74 (0.24–12.61) 1.67 (0.62–4.50)
Multivariate-adjusted HR (model 4) 1.64 (0.53–5.14) 1.73 (0.24–12.52) 1.68 (0.62–4.50)
Major → Minor 40 Cases 6 1 7
Age-adjusted and gender-adjusted HR
(model 1)
1.88 (0.84–4.21) 1.11 (0.16–7.95) 1.73 (0.82–3.66)
Multivariate-adjusted HR (model 2) 1.74 (0.78–3.91) 0.98 (0.14–7.02) 1.58 (0.75–3.34)
Multivariate-adjusted HR (model 3) 1.73 (0.77–3.89) 0.96 (0.13–6.92) 1.57 (0.74–3.31)
Multivariate-adjusted HR (model 4) 1.69 (0.75–3.80) 0.94 (0.13–6.73) 1.52 (0.72–3.22)
Major → Major 191 Cases 44 19 61
Age-adjusted and gender-adjusted HR
(model 1)
3.01 (2.21–4.10)*** 4.54 (2.81–7.32)*** 3.37 (2.59–4.39)***
Multivariate-adjusted HR (model 2) 2.23 (1.62–3.07)*** 3.65 (2.22–6.02)*** 2.56 (1.95–3.36)***
Multivariate-adjusted HR (model 3) 2.23 (1.61–3.08)*** 3.67 (2.20–6.10)*** 2.56 (1.94–3.37)***
Multivariate-adjusted HR (model 4) 2.15 (1.55–2.98)*** 3.62 (2.17–6.05)*** 2.48 (1.88–3.28)***
Model 2: covariates were age, gender, systolic blood pressure, antihypertensive medication, body mass index, smoking category (never, past or current smokers), alcohol intake category
(never, past, current <46, current ≥46 g/day), serum total cholesterol and diabetic type.
Model 3: covariates comprised model 2 plus other ECG abnormalities (high R-wave, ventricular premature beats, atrial fibrillation) at study entry.
Model 4: covariates comprised model 3 plus changes in other ECG abnormalities (high R-wave, ventricular premature beats, atrial fibrillation) during follow-up.
*p<0.05, **p<0.01, ***p<0.001.
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reported that a new depression of the ST segment (Minnesota
Code 4-1 and 4-2) and a new T-wave abnormality (Minnesota
Code 5-1, 5-2 and 5-3) were associated with a twofold to three-
fold increased risk of CVD mortality.3 In that study, persistent
ST-T abnormalities were associated with a ﬁvefold to sixfold
increased risk of CVD mortality (albeit with a small number of
CVD deaths). An 8-year follow-up study of 2192 US citizens
aged 70–79 years that collected repeat ECGs at baseline and
4 years after showed that new ECG abnormalities (either of
Minnesota Code 1-1 to 1-2-8, 3-1, 4-1 to 4-4, 5-1 to 5-4,
6-4-1, 6-4-2, 7-1-1, 7-2-1, 7-4, 7-8 or 8-3) were associated with
a twofold increased risk of subsequent CHD events.4 In that
study, persistent abnormalities were associated with a 1.5-fold
increased risk of CHD.
The present study had three key ﬁndings. First, abnormality
groups that changed from none to minor during 11-year annual
surveys were associated with CVD risk. Second, even for a
minor abnormality, if it worsens over time, then it should be
considered to be a clinically signiﬁcant ﬁnding for a high-risk
individual. Third, persistent major abnormalities on repeat
ECGs carried a higher risk of CVD than new major
abnormalities.
It is noteworthy that we observed weak and non-signiﬁcant
associations between ST-T abnormality changes from none to
major and risk of CVD after adjustment for known cardiovascu-
lar risk factors. These associations were attenuated substantially
when systolic BP and antihypertensive medication were taken
into account, which means that hypertension mainly con-
founded the association.
Our study showed differences between men and women for
the association between ischaemic ECG abnormalities and CVD
risk. The association between changes in a Code4 abnormality
and CVD risk was conﬁned to men. Absence of such an associ-
ation in women may be a result of the higher prevalence of a
minor Code4 abnormality.2 In the present study, the prevalence
of a Code4 abnormality was twofold higher in women than in
men. It is well known that women are more likely to have
minor ST-T abnormalities as a normal physiological variant.
Confounding by other ECG abnormalities should be consid-
ered. High R-wave, ventricular premature beats and atrial ﬁbril-
lation at study entry were associated with an increased risk of
total CVD, as shown previously.10–12 When we adjusted further
for these ECG abnormalities at study entry and during 10
annual examinations, the result for total CVD did not change.
The potential mechanism of action for the association
between the presence, appearance or advancement of ST-T
abnormalities and CVD risk warrants discussion. ST-T abnormal-
ities are caused by myocardial ischaemia, hypokalaemia and
certain drugs,13 but the most common cause in a general popu-
lation is slight-to-moderate myocardial ischaemia. Usually, myo-
cardial ischaemia is caused by atherosclerosis and/or
arteriolosclerosis in coronary arteries, and also accompanied by
these pathological changes in other vascular systems (ie, athero-
sclerosis in large cerebral arteries and arteriolosclerosis in small
cerebral arteries).14 15 Therefore, ST-T changes should be a sur-
rogate marker for disease in large and small vessels, which lead
to an increased risk of stroke and CHD.
The strength of the present study, compared with previous
studies,3 4 was the long follow-up of a large population of men
and women in whom repeat ECGs were available during
11 years. The limitation of our study was the small number of
CVD events in the major–no and major–minor abnormality
groups, in which the relationship between the ECG abnormality
and CVD risk was not examined thoroughly.
CONCLUSION
Changes in ischaemic ECG abnormalities from none to minor,
and minor to major, as well as persistent major abnormalities,
are associated with an increased risk of CVD in a general
population.
Key messages
What is already known about this subject?
ST-T abnormalities in ECG at study entry are associated with an
increased risk of cardiovascular disease (CVD) among Europeans
and Americans.
What does this study add?
Changes in ischaemic ECG abnormalities from none to minor,
and minor to major, as well as persistent major abnormalities,
are associated with an increased risk of CVD among Asians.
How might this impact on clinical practice?
Repeated measurements of annual ECGs are useful for more
precise prediction of CVD.
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